Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Ocumension Files for Hong Kong IPO to Advance Ophthalmology Portfolio

publication date: Apr 30, 2020

Ocumension Therapeutics, a Shanghai biopharma incubated by 6 Dimensions Capital, has filed for a Hong Kong IPO. Just three years old, Ocumension has built a portfolio of 16 ophthalmology drugs for China development largely through in-licensings. The portfolio includes four candidates in or near clinical development. The company's most advanced product is an intravitreal sustained-release corticosteroid implant to treat uveitis. Ocumension says it has acquired China rights to three of ten ophthalmic drugs approved in the US since 2015, but not available in China. The company is also developing its own ophthalmology drugs. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital